KALA BIO Reports Third Quarter 2024 Financial Results and Provides Corporate Update
12 nov. 2024 08h00 HE
|
KALA BIO, Inc.
-- Ongoing patient enrollment in Phase 2b CHASE trial of KPI-012 in Persistent Corneal Epithelial Defect (PCED); topline results expected in 2Q 2025 -- -- Initiated five clinical trial sites for the...
KALA BIO to Present at H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
08 août 2024 08h00 HE
|
KALA BIO, Inc.
ARLINGTON, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of...
KALA BIO Reports Second Quarter 2024 Financial Results and Provides Corporate Update
06 août 2024 08h00 HE
|
KALA BIO, Inc.
-- Closed $12.5 million private placement financing led by SR One with participation from ADAR1 Capital Management and another life sciences-focused investor – -- Cash resources of $54.2 million as...
KALA BIO Announces $12,500,000 Private Placement
27 juin 2024 08h00 HE
|
KALA BIO, Inc.
ARLINGTON, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of...
KALA BIO to Present at Jefferies Global Healthcare Conference
29 mai 2024 08h00 HE
|
KALA BIO, Inc.
ARLINGTON, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative...
KALA BIO Reports First Quarter 2024 Financial Results and Provides Corporate Update
14 mai 2024 16h05 HE
|
KALA BIO, Inc.
-- Patient enrollment ongoing in Phase 2b CHASE trial of KPI-012 for PCED; targeting topline data by year-end 2024 -- -- Evaluating opportunities to expand KPI-012 development into other corneal...
KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
29 mars 2024 08h00 HE
|
KALA BIO, Inc.
-- Advancing ongoing Phase 2b CHASE trial of KPI-012 for PCED; topline data targeted by year-end 2024 ---- Exploring opportunities to expand KPI-012 into additional corneal indications ---- Cash...
KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference
26 févr. 2024 08h00 HE
|
KALA BIO, Inc.
ARLINGTON, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of...
KALA BIO to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
06 févr. 2024 08h00 HE
|
KALA BIO, Inc.
ARLINGTON, Mass., Feb. 06, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of...
KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
19 janv. 2024 16h01 HE
|
KALA BIO, Inc.
ARLINGTON, Mass., Jan. 19, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (Nasdaq:KALA), today announced that the Company granted non-statutory stock options to a new employee as an inducement award...